ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CGEN Compugen Ltd

2.005
0.075 (3.89%)
Last Updated: 19:35:32
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compugen Ltd NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.075 3.89% 2.005 2.00 2.01 2.02 1.875 1.93 218,091 19:35:32

Compugen to Present at the Jefferies Global Healthcare Conference in New York

23/05/2016 12:00pm

PR Newswire (US)


Compugen (NASDAQ:CGEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Compugen Charts.

HOLON, Israel, May 23, 2016 /PRNewswire/ --

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016.

About Compugen 

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892

SOURCE Compugen Ltd.

Copyright 2016 PR Newswire

1 Year Compugen Chart

1 Year Compugen Chart

1 Month Compugen Chart

1 Month Compugen Chart

Your Recent History

Delayed Upgrade Clock